Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
SMT-NK + pembrolizumab
- Development stage
- Unknown
- Lead developer
- SMT bio
- Modality
- CAR-NK Cells → Other Engineered Cells → Adoptive Cell Transfer → Cell Therapies, Monoclonal Antibodies → Antibody-Based Therapeutics, Lymphokine-Activated Killer Cells → Native Immune Cells → Adoptive Cell Transfer → Cell Therapies
- Administration
- Intravenous
01
Overview
SMT-NK + pembrolizumab is a combination investigational cancer immunotherapy consisting of highly activated allogeneic natural killer (NK) cells (SMT-NK) and the anti-PD-1 monoclonal antibody pembrolizumab. SMT-NK, developed by SMT Bio, is an off-the-shelf NK cell therapy designed to enhance innate immune responses against tumor cells. Pembrolizumab (Keytruda), developed by Merck & Co., is a checkpoint inhibitor that blocks the programmed death receptor 1 (PD-1) on T-cells, preventing tumor-induced immune suppression and enabling T-cell mediated antitumor activity. The combination aims to synergistically boost both innate and adaptive immunity for improved efficacy in treating advanced biliary tract cancer, particularly in patients refractory to standard chemotherapy. Clinical trials have shown that this regimen can be safely administered with no severe adverse events directly related to the combination and has demonstrated improved antitumor activity compared to monotherapy with pembrolizumab[3][5][6][8].
- Other names
- allogeneic natural killer cell therapy + pembrolizumabNK cell therapy + pembrolizumab
02
Targets
PDCD1 (Programmed cell death protein 1 receptor)
Beyond the preview
Go deeper on SMT-NK + pembrolizumab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on SMT-NK + pembrolizumab.